Skip to main content
Caplight Logo









Promakhos Therapeutics

Promakhos Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.promakhos.com/

Last Round

Grant

May 6, 2026

Est. Valuation

$1.79M

Total Funding Raised

$794,365

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Promakhos Therapeutics is a biotechnology company developing advanced, targeted, immune-modulating therapies for autoimmune and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoverysmall-molecule therapyimmune modulationinnate immunitycrohn's diseaseprecision medicinesingle-cell profilingcomputational biologybiotech startupdrug pipelinepreclinical researchtherapeutic developmentai-driven drug discoveryin silico drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Promakhos Therapeutics Comparables

Compare Promakhos Therapeutics with similar companies based on industry and business-model similarity.

Promakhos Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Piton Therapeutics
83%
Ensho Therapeutics
81%
Eli Lilly and Company
72%

Promakhos Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 6, 2026
GrantFeb 19, 2024
GrantJan 24, 2024
GrantSep 1, 2023
AcceleratorOct 31, 2021
Accelerator
Jul 15, 2021

Key People

Founding team and executive leadership

Jasper E. Neggers

Co-Founder, Chief Scientific Officer, Secretary

Founding Team

Promakhos Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2026

    $75K grant from Harvard President's Innovation Challenge.

  • Feb 19, 2024

    $100K grant from Massachusetts Life Sciences Center

Promakhos Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Promakhos Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Promakhos Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range3
Year Founded2021
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?